Industry news
AstraZeneca, MedImmune, and Moderna Therapeutics to collaborate on mRNA therapy
AstraZeneca, along with its global biologics research and development arm, MedImmune, and Moderna Therapeutics has announced a new collaboration to discover, co-develop and co-commercialise messenger RNA (mRNA) therapeutic candidates for the treatment of a range of cancers. The collaboration is in addition to the agreement announced by the companies in 2013 to develop mRNA Therapeutics for the treatment of cardiovascular, metabolic and renal diseases as well as selected targets in oncology.